Idenix Pharmaceuticals (IDIX)

[go seek]

VALOPICITABINE (NM283), ALONE OR WITH PEG-INTERFERON, COMPARED TO PEG INTERFERON/RIBAVIRIN (PEGIFN/RBV) RETREATMENT IN PATIENTS WITH HCV-1 INFECTION AND PRIOR NON-RESPONSE TO PEGIFN/RBV: ONE-YEAR RESULTS

this study to be reported 4:15p Barcelona time... 10:15a NY time Thursday 12 April

not expecting anything new here... ie. verification refractory (retreatment)HCV patients difficult group to treat


Abstract Conclusions: W48 results continue to support valopicitabine as a component of future combination regimens for patients who have failed pegIFN/RBV therapy, but also demonstrate the difficulty in fully suppressing HCV replication in NR patients. Final SVR data will be available. Due to the minimal efficacy contribution by pegIFN/RBV, combination therapy for NRs will likely require the contribution of two or more novel and complementary agents for optimal clinical outcomes.

http://www.easl.ch/liver-meeting/Program/ViewAbstract.asp